SCIENCE: An open-label trial in Friedreich ataxia suggests clinical benefit with high-dose resveratrol, without effect on frataxin levels.

Speech sensitive to treatment response

J Neurol. 2015 May;262(5):1344-53. doi: 10.1007/s00415-015-7719-2

Related Post

  • Posted on 27 April, 2023
    Redenlab have been featured in the Huberman Lab Podcast for their study on “Adults with a history of recreational cannabis...
    • Posted on 30 March, 2023
      L16HTHOUSE is a research trial testing an experimental medication for treating speech, motor, learning, and other developmental delays in children...
      • Posted on 30 March, 2023
        Speech and language development is a complex, multifactorial process driven by the individual’s ability to process and formulate communication. These...